Kidney cancer affects tens-of-thousands every year, but research and care advances are improving survival chances and quality of life for patients. Kidney cancer occurs more frequently than many ...

Cancer before age 50 is rare, but increasing, in the United States and researchers want to know why. A new government study provides the most complete picture yet of early-onset cancers, finding that ...

Personalized neoantigen vaccines show promise in activating immune responses and controlling tumors in kidney cancer patients. A phase 1 trial demonstrated neoantigen-specific T-cell responses and ...

Keytruda and Lenvima combination showed a 50.6% overall response rate and 82.3% disease control rate in advanced non-clear cell kidney cancer. The median progression-free survival was 17.9 months, ...